Literature DB >> 32880036

Measuring What Matters to Individuals with Angelman Syndrome and Their Families: Development of a Patient-Centered Disease Concept Model.

Tom Willgoss1, Daiana Cassater2, Siobhan Connor3, Michelle L Krishnan2, Meghan T Miller2, Carla Dias-Barbosa4, Dawn Phillips5, Julie McCormack6, Lynne M Bird7, Rebecca D Burdine8, Sharon Claridge9, Terry Jo Bichell10.   

Abstract

Angelman syndrome (AS) is a complex, heterogeneous, and life-long neurodevelopmental disorder. Despite the considerable impact on individuals and caregivers, no disease-modifying treatments are available. To support holistic clinical management and the development of AS-specific outcome measures for clinical studies, we conducted primary and secondary research identifying the impact of symptoms on individuals with AS and their unmet need. This qualitative research adopted a rigorous step-wise approach, aggregating information from published literature, then evaluating it via disease concept elicitation interviews with clinical experts and caregivers. We found that the AS-defining concepts most relevant for treatment included: impaired expressive communication, seizures, maladaptive behavior, cognitive impairment, motor function difficulties, sleep disturbance, and limited self-care abilities. We highlight the relevance of age in experiencing these key AS concepts, and the difference between the perceptions of clinicians and caregivers towards the syndrome. Finally, we outline the impact of AS on individuals, caregivers, and families.

Entities:  

Keywords:  Angelman syndrome; Clinical endpoint; Outcome assessment; Patient-centered; Qualitative research

Year:  2021        PMID: 32880036     DOI: 10.1007/s10578-020-01051-z

Source DB:  PubMed          Journal:  Child Psychiatry Hum Dev        ISSN: 0009-398X


  1 in total

1.  Molecular and Clinical Aspects of Angelman Syndrome.

Authors:  A Dagli; K Buiting; C A Williams
Journal:  Mol Syndromol       Date:  2011-07-28
  1 in total
  5 in total

1.  Clinical Characterization of Epilepsy in Children With Angelman Syndrome.

Authors:  Daiana Cassater; Mariana Bustamante; Lisa Sach-Peltason; Alexander Rotenberg; Mark Nespeca; Wen-Hann Tan; Lynne M Bird; Joerg F Hipp
Journal:  Pediatr Neurol       Date:  2021-08-31       Impact factor: 3.372

Review 2.  Gene-based therapeutics for rare genetic neurodevelopmental psychiatric disorders.

Authors:  Beverly L Davidson; Guangping Gao; Elizabeth Berry-Kravis; Allison M Bradbury; Carsten Bönnemann; Joseph D Buxbaum; Gavin R Corcoran; Steven J Gray; Heather Gray-Edwards; Robin J Kleiman; Adam J Shaywitz; Dan Wang; Huda Y Zoghbi; Terence R Flotte; Sitra Tauscher-Wisniewski; Cynthia J Tifft; Mustafa Sahin
Journal:  Mol Ther       Date:  2022-05-17       Impact factor: 12.910

3.  Improvement in Gait and Participation in a Child with Angelman Syndrome after Translingual Neurostimulation Associated with Goal-Oriented Therapy: A Case Report.

Authors:  Delphine Gaudin-Drouelle; Laetitia Houx; Mathieu Lempereur; Sylvain Brochard; Christelle Pons
Journal:  Children (Basel)       Date:  2022-05-13

4.  A Patient-Centered Conceptual Model of Symptoms and Their Impact in Early Parkinson's Disease: A Qualitative Study.

Authors:  Hannah Staunton; Kim Kelly; Louise Newton; Mathias Leddin; Raul Rodriguez-Esteban; K Ray Chaudhuri; Daniel Weintraub; Ronald B Postuma; Pablo Martinez-Martin
Journal:  J Parkinsons Dis       Date:  2022       Impact factor: 5.568

5.  Multidimensional analysis of behavior predicts genotype with high accuracy in a mouse model of Angelman syndrome.

Authors:  Joseph K Tanas; Devante D Kerr; Li Wang; Anika Rai; Ilse Wallaard; Ype Elgersma; Michael S Sidorov
Journal:  Transl Psychiatry       Date:  2022-10-03       Impact factor: 7.989

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.